SRS16-86

• Description :

  SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Ferroptosis

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/srs16-86.html

• Purity :

  98.0

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles :

  O=C(C1=CC(/N=C\C2=CN=CN=C2)=C(C=C1)NC3(C[C@H](C4)C5)C[C@H]5C[C@H]4C3)OC(C)(C)C

• Molecular Formula :

  C26H32N4O2

• Molecular Weight :

  432.56

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Sam Hofmans, et al. Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. J Med Chem. 2016 Mar 10;59 (5) :2041-53.|[2]Andreas Linkermann, et al. Synchronized renal tubular cell death involves ferroptosis.Proc Natl Acad Sci U S A. 2014 Nov 25;111 (47) :16836-41.|[3]Yan Zhang, et al. Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. Brain Res. 2019 Mar 1;1706:48-57.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1793052-96-6]